To evaluate the safety and effectiveness of Ivonescimab combined with intraperitoneal paclitaxel (IP PTX) in patients with unresectable metastatic high-grade A…

Phase IIIvonescimabIntraperitoneal+3 more

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07753824

Phase 1

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metasta…

Metastatic Appendiceal AdenocarcinomaIntraperitoneal Paclitaxel

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06207305